At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 86 enrolled
Drug / intervention
HB-01 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of HB-1 for Panic Disorder: A Multicenter, Randomized, Double Blind, Placebo-Controlled Trial
In Brief
A Phase 2 clinical trial evaluating HB-01 and Placebo for Panic Disorder. Completed, enrolled 86 participants across 10 sites.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of potential new treatment called "HB-1" versus placebo in male and female adult patients aged 18 to 60 years, inclusive, with panic disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPanic Disorder
CountriesUnited States
CollaboratorsCognitive Research Corporation
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartFeb 2022
Primary CompletionDec 2022
TodayJul 2026
First PostedOct 8, 2021
Enrollment StartFeb 3, 2022
Primary CompletionDec 12, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.7 years ago
Interventions
HB-01drug
HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
Placebodrug
HB-1 matched placebo